Venetoclax in the treatment of chronic lymphocytic leukemia
A Korycka-Wolowiec, D Wolowiec… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Venetoclax, an antagonist of BCL-2 protein plays an important role in the
pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for …
pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for …
Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax
M Waldron, A Winter, BT Hill - Clinical pharmacokinetics, 2017 - Springer
Management of chronic lymphocytic leukemia has changed markedly over the last several
years with the emergence of several novel oral agents targeting B-cell receptor and Bcl-2 …
years with the emergence of several novel oral agents targeting B-cell receptor and Bcl-2 …
[HTML][HTML] A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies
Molecular targeted therapies are based upon drugs acting on tumors by interfering with
specific targets involved in growth and spread of cancer. Many targeted therapies were …
specific targets involved in growth and spread of cancer. Many targeted therapies were …
The safety of available chemo-free treatments for mantle cell lymphoma
A Korycka-Wołowiec, D Wołowiec… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Introduction Conventional treatment for mantle cell lymphoma (MCL) patients includes
regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation …
regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation …
[HTML][HTML] Adenosine 2A receptor activation amplifies ibrutinib antiplatelet effect; implications in chronic lymphocytic leukemia
O Elaskalani, G Gilmore, M Hagger, RI Baker… - Cancers, 2022 - mdpi.com
Simple Summary A significant number of patients with chronic lymphocytic leukemia (CLL)
have an increased risk of bleeding. This risk is further increased when taking ibrutinib, a new …
have an increased risk of bleeding. This risk is further increased when taking ibrutinib, a new …
Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych
A Kubiak-Mlonka, E Ziółkowska… - Acta Haematologica …, 2019 - journals.viamedica.pl
Wenetoklaks jest przedstawicielem nowej grupy leków, których mechanizm działania polega
na zahamowaniu ekspresji antyapoptotycznych białek rodziny BCL-2. Białka te należą do …
na zahamowaniu ekspresji antyapoptotycznych białek rodziny BCL-2. Białka te należą do …